Moreau P, Attal M, Pégourié B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117(11):3041–3044.

On page 3043 in the 17 March 2011 issue, there are errors in the Figure 1 legend; the P values are correct. The corrected legend sections should have read as listed below. The corrected Figure 1 legend is shown.

• achievement of VGPR after induction versus < VGPR

• correct

• achievement of VGPR after induction in VAD and bortezomib-dexamethasone arms versus < VGPR

• correct

• correct

• achievement of VGPR after induction in ISS stages 2 and 3 versus < VGPR

• achievement of VGPR after induction in poor-risk cytogenetics versus < VGPR

Figure 1. Progression-free survival. (A) Achievement of VGPR after induction therapy versus < VGPR; (B) achievement of VGPR after induction versus after high-dose therapy; (C) achievement of VGPR after induction in VAD and bortezomib-dexamethasone arms versus < VGPR; (D) ISS stages 2 and 3, bortezomib-dexamethasone induction versus VAD; (E) poor-risk cytogenetics, bortezomib-dexamethasone induction versus VAD; (F) achievement of VGPR after induction in ISS stages 2 and 3 versus < VGPR; (G) achievement of VGPR after induction in poor-risk cytogenetics versus < VGPR. (A) P < .0001; (B) P = .01; (C) P < .0001; (D) P = .006; (E) P = .11; (F) P < .0001; and (G) P = .0036.